AI Article Synopsis

Article Abstract

The longitudinal follow-up of a patient with an advanced adenocarcinoma of the ovary sheds new light on the involvement of the pineal in carcinogenesis. The changes in the circadian MESOR of 6-sulfoxy-melatonin following a course of chemotherapy may differ in relation to the success or failure of treatment, yet the MESOR does not correlate with tumor burden assessed by circulating CA125. By contrast, the ratio of circaseptan-to-circadian amplitudes involving two chronome components correlates with the cancer marker. To that extent, the study reveals a critical about 7-day (circaseptan) aspect of the pineal involvement in cancer progression. This information could be exploited in designing schedules of melatonin administration to cancer patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

circulating ca125
8
cancer progression
8
chronome urinary
4
urinary 6-sulfoxy-melatonin
4
6-sulfoxy-melatonin excretion
4
excretion circulating
4
cancer
4
ca125 cancer
4
progression therapeutic
4
therapeutic response
4

Similar Publications

Soluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes. Emerging evidence suggests that carbohydrate antigen 125 (CA125) may act as a ligand that modulates the inflammatory response.

View Article and Find Full Text PDF

Background: The ovarian cancer (OC) preclinical detectable phase (PCDP), defined as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Methods: In UKCTOCS between Apr-2001 and Sep-2005, 101,314 postmenopausal women were randomised to no screening (NS) and 50,625 to annual multimodal screening (MMS) (until Dec-2011) using serum CA-125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA).

View Article and Find Full Text PDF

Circulating tumor DNA detection improves relapse prediction in epithelial ovarian cancer.

BMC Cancer

December 2024

Department of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Epithelial ovarian cancer (EOC) is a lethal form of gynecological malignancy. Some EOC patients experience relapse after standard primary debulking surgery (PDS) and adjuvant chemotherapy (ACT). Identifying molecular residual disease (MRD) by circulating tumor DNA (ctDNA) detection can timely signal the potential for relapse.

View Article and Find Full Text PDF

Background: Biomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK trial.

Methods: Subjects with IPF were randomised 1:2 to receive nintedanib 150 mg twice daily or placebo for 12 weeks, after which all patients received open-label nintedanib for 40 weeks.

View Article and Find Full Text PDF

Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study.

J Thorac Dis

November 2024

Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Background: There is uncertainty with respect to the baseline tumor markers and clinical outcomes for patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The study aimed to assess the association between baseline tumor markers and progressive pulmonary fibrosis (PPF) and prognosis.

Methods: This is a prospective cohort study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!